Background: In a phase III trial (ClinicalTrials.gov registration ID: NCT00094653), ipilimumab significantly improved survival versus a vaccine control in pretreated patients with metastatic melanoma. Here, we characterize outcomes of those patients who survived ≥2 years.
introduction
Before the availability of ipilimumab, approved treatment options for patients with metastatic melanoma were limited and despite concerted efforts over many decades, overall survival (OS) remained disappointing [1] .
Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) that augments T-cell activation and proliferation to enhance the immune response against tumors, was the first agent to show a survival benefit in patients with metastatic melanoma enrolled in a phase III trial [2] . Ipilimumab 3 mg/kg significantly improved survival in patients with previously treated, metastatic melanoma compared with a vaccine control [hazard ratio (HR): 0.66; P = 0.003], with estimated 1-and 2-year survival rates of 45.6% versus 25.3% and 23.5% versus 13.7%, respectively [2] . In 2011, ipilimumab was approved at a dose of 3 mg/kg for pretreated and treatment-naïve adult patients with metastatic melanoma.
By contrast with chemotherapy, where responses are typically transient, clinical benefit with ipilimumab tends to be durable, lasting months and even years in some patients. Extended follow-up from phase II trials consistently show a plateau in survival curves with a meaningful proportion of patients surviving 5 or more years from the start of treatment [3] .
Ipilimumab also differs from chemotherapy in that it is associated with characteristic spectrum of adverse events (AEs) resulting from increased or excessive immune activity, likely to be related to its mechanism of action. Immune-related AEs (irAEs), which can be severe or life-threatening, may involve the gastrointestinal (GI), liver, skin, nervous, endocrine, or other organ systems. However, they are mostly mild and generally manageable with appropriate treatment, including the use of systemic high-dose corticosteroids in patients with severe (grade 3 or 4) irAEs.
Improved understanding of the safety profile of patients treated with ipilimumab is very important. Some data suggest that developing an irAE may be associated with clinical benefit and that patients who develop irAEs may survive longer; however, other studies have shown no correlation between efficacy and toxic effect [4, 5] . In addition, little is known regarding the types and impact of toxic effects that occur beyond the initial dosing period or late, new-onset events that are observed a fixed time after the last dose.
The objective of this analysis is to describe the safety and longterm efficacy of ipilimumab among patients from the pivotal phase III MDX010-20 study who survived 2 years or longer.
methods
Full details of the phase III MDX010-20 study (trial registration ID: NCT00094653), including the study design, inclusion and exclusion criteria, treatment, response assessment, endpoints, and statistical analysis methods have been published previously [2] . Briefly, a total of 676 patients with unresectable stage III or IV melanoma who had been treated previously with chemotherapy or interleukin-2 (IL-2) were randomized 2 : 1 : 1 to receive ipilimumab plus gp100 vaccine, ipilimumab alone or gp100 alone every 3 weeks for four doses.
Tumor responses were assessed using modified World Health Organization response criteria and AEs were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0 [2] . IrAEs were defined as any event associated with study drug exposure that was consistent with an immune phenomenon. Patients with an objective tumor response or stable disease of ≥3 months' duration were eligible for retreatment with their assigned treatment regimen upon evidence of disease progression [2, 6] .
results

efficacy
Of 676 patients treated in MDX010-20, 474 were randomized at least 2 years before the study cut-off date and were eligible for this analysis. Of the 474 patients, 94 (20%) survived ≥2 years, comprising 54 of 284 (19%) patients treated with ipilimumab plus gp100, 24 of 95 (25%) treated with ipilimumab alone, and 16 of 95 (17%) treated with vaccine alone. Of these 94 patients, 5 (5%) had brain metastases comprising 3 patients treated with ipilimumab plus gp100, and 1 patient treated with ipilimumab alone or gp100 alone, respectively. Among patients who survived ≥2 years, 42 of 94 (45%) survived at least ≥3 years (Table 1) .
Of 38 ipilimumab-treated patients who achieved complete or partial tumor responses as their best on-study response [7] , 25 (66%) survived ≥2 years, and of 82 patients who had stable disease (SD) as their best on-study response, 31 (38%) survived for 2 years or longer. Among 309 patients whose best on-study response was progressive disease (PD), 21 (7%) survived ≥2 years (Table 2 ).
Baseline characteristics of the patients who survived ≥2 years were comparable across the three treatment groups (Table 3) . However, when compared with patients who survived <1 year (Table 4) , some baseline characteristics appeared to be associated with longer survival. For example, of the 81 patients treated with ipilimumab alone who survived <1 year, 66 (82%) had M1c disease at baseline compared with 12 (50%) of the 24 patients who survived more than 2 years. Similarly, for patients treated with ipilimumab plus gp100 or gp100 alone, 80% and 74% of patients surviving <1 year had M1c disease, respectively, compared with 56% and 63% patients surviving ≥2 years. Compared with patients who survived <1 year, a higher percentage of patients who had received prior treatment with IL-2, had an ECOG PS of 0, or had lactate dehydrogenase (LDH) levels below the upper limit of normal (ULN), survived ≥2 years. AEs were monitored from the first induction dose until at least 70 days after the last induction dose of ipilimumab had been administered. During this period, safety in patients with ≥2 years' survival was comparable to that in the overall study population. Among the 78 ipilimumab-treated patients, 11 (14%) had a high grade irAE between the first induction dose and 70 days after last induction dose, comprising 7 patients treated with ipilimumab plus gp100 and 4 patients treated with ipilimumab alone. This was similar to the overall study population, where high grade irAEs occurred in 43 (11%) patients treated with ipilimumab plus gp100 and 20 (15%) patients treated with ipilimumab alone. Seven patients (7%) had irAEs that occurred more than 70 days after the last dose, comprising 5 patients treated with ipilimumab plus gp100, and 1 treated with ipilimumab alone or gp100 alone, respectively. With the exception of one incidence of grade 3 colitis, all new cases were low-grade events, including grade 1 vitiligo and diarrhea and grade 2 hypogonadism and proctitis (Table 5 ). In the overall study population, 6 of 45 patients (14%) experienced a grade ≥2 irAE more than 3 months after the last induction dose.
discussion
Ipilimumab therapy was associated with survival of at least 2 years in approximately one-fifth of qualifying patients enrolled in MDX010-20. Patients who received ipilimumab with gp100 vaccine and who survived for ≥2 years represent 19% of patients who had 2 years of potential follow-up, and among patients who were followed for 3 years, 15% were still alive at ≥3 years. Corresponding actual survival for the ipilimumab monotherapy subgroup was 25% at both timepoints.
The differences in survival outcome between the two ipilimumab groups described above, albeit small, together with data from the overall MDX010-20 study population and a recent phase II adjuvant trial of ipilimumab, suggests the addition of the gp100 peptide does not improve ipilimumab efficacy. However, in a separate phase III trial, adding the vaccine to IL-2 significantly improved response rates and resulted in longer OS compared with IL-2 alone. This disparity may point to the distinct mechanisms of action of different immunotherapies, and requires further investigation in prospective trials [2, 8, 9] .
The 2-and 3-year survival rates from this analysis benchmark favorably against long-term survival reported after first-line dacarbazine (11% at ≥1.5 years and 5% at 3 years), or high-dose IL-2 bolus regimen (15% at 2 years) or continuous infusion regimen (6% at 3 years) [10] [11] [12] [13] . However, survival rates reported here are binomial and only determined in patients with the potential to live at least 2 or 3 years. In the trials described above, survival rates would likely have been determined by Kaplan-Meier analysis of the entire study population. Although useful to reference against historical data, the survival rates cannot be compared directly and should be considered accordingly.
Importantly, long-term survival occurred in the absence of continued ipilimumab treatment. Unlike cytotoxic chemotherapy or molecularly targeted agents, where continued treatment appears necessary to maintain efficacy, continued disease regression is frequently observed with ipilimumab long after completion of the initial induction period. If cancer patients have a heterogeneous pool of tumor-specific cytotoxic T cells, including naïve, effector and memory T cells, it is possible that inhibition of CTLA-4 with ipilimumab could original articles Annals of Oncology enhance immune memory responses, thus increasing long-term survival through the inhibition of metastasis and prevention of relapse [14] . Long-term survival outcomes from ipilimumab treatment in this study were obtained mostly in pretreated patients who had progressed on, or were unable to tolerate previous therapies, including prior IL-2. Other analyses have shown safety and efficacy data with ipilimumab to be similar, irrespective of prior IL-2 treatment [15, 16] . Interestingly, although the proportion of patients who had received prior IL-2 was balanced across the three treatment arms, more long-term survivors treated with ipilimumab plus gp100 appeared to have received prior IL-2 than long-term survivors treated with ipilimumab or gp100 alone. Small patient numbers precluded statistical analysis; however, this is an interesting observation that warrants further investigation. Pretreated patients are an especially challenging population for whom therapeutic options are limited typically to enrolment in clinical trials. Ipilimumab has demonstrated a durable survival benefit in these patients, an encouraging finding for its potential efficacy in an earlier setting. Indeed, in the phase III trial investigating ipilimumab at a higher dose (10 mg/kg) and administered in combination with dacarbazine in previously untreated patients, survival was noted among some patients followed for up to 4 years. In the entire study population, an estimated 28.8%, 21.2%, and 19.0% of patients were alive at 2, 3, and 4 years, respectively [17, 18] . Similar to this analysis, a survival update of this trial found that in comparison with the total population, a lower percentage of patients who survived at least 4 years had M1c disease, and a higher percentage had an ECOG PS of 0 and LDH <ULN [18] .
Among ipilimumab-treated patients surviving at least 2 years, 56 (72%) achieved disease control (complete or partial tumor response or SD as their best response) compared with 120 of 540 (22%) of patients in MDX010-20 who achieved disease control between starting ipilimumab treatment and week 24 [2] ; thus suggesting these responses may be associated with longterm survival. Of note, a key feature distinguishing therapy with ipilimumab from chemotherapy is the heterogeneity of response timing [19] . Responses can manifest later and may be more durable compared with those seen with chemotherapy and can be preceded by disease progression or inflammation that can appear on scans as PD. Of the 78 patients who received ipilimumab in the phase III trial and survived 2 years or longer, 12 improved beyond week 24, including patients who improved from PD to SD, from SD to partial response (PR), and from PR to CR [7] . Thus, in some patients, an improvement in best response occurred after completion of induction therapy, and the possibility of late-onset responses should be factored into any assessment schedule of ipilimumab therapy.
On-treatment safety in the subset of long-term survivors was comparable to that in the overall study population [2] . Once treatment had ended, irAEs subsided, with only seven patients reporting irAEs during follow-up. All events were grade 1 or 2, with the exception of one patient who had grade 1 diarrhea, grade 2 proctitis, and grade 3 colitis. This patient recovered by day 147, with residual effects. There did not appear to be an association between safety and efficacy in this analysis, as has been previously described [4] . Thus, among patients with metastatic melanoma, mechanism-related toxic effect with ipilimumab 3 mg/kg does not appear to present any new challenges in the long term, and in short term, these AEs can be managed with prompt recognition and treatment per defined algorithms [20] . Treatment of low-grade events is symptomatic; however, ongoing vigilance is necessary to prevent complications or exacerbation. Data from specific evaluations suggest that treating higher-grade irAEs with corticosteroids does not compromise ipilimumab efficacy, including for longterm responses [21, 22] .
It is important to note that the number of patients in this analysis is small; therefore, findings need to be confirmed prospectively in larger data sets where statistical analysis is possible. In addition, further studies are required to identify and categorize specific patient characteristics and/or biomarkers that may be associated with ipilimumab clinical efficacy. The ability to identify which patients will survive longer, before starting treatment, will help maximize patient outcomes associated with this immunotherapeutic agent. 
